anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

129,181-129,240 of 319,975

filter-aware
46
The slide uses legal filings and OIG reports to establish a pattern of billing abuse in the sleep sector.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
47
The slide uses direct quotes from two different medical professionals to highlight a pattern of disregard for safety protocols.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
48
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
49
Includes a process diagram showing the progression from hERG block to Torsades de Pointes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
50
The slide uses red underlining to emphasize key risk statements, likely to draw attention to the severity of the condition in the context of a drug evaluation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The StruggleLoop · The Reveal1 hit
51
The slide uses a quote from a 2004 NEJM paper to establish a precedent of drug withdrawal, then links the molecular structure (piperidine ring) and receptor activity of pitolisant to these withdrawn drugs.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
52
The slide uses historical news headlines to illustrate the regulatory and safety failure of the drug Seldane.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
53
The slide uses a historical precedent (Seldane/terfenadine recall) to frame the severity of a current drug's (pitolisant) safety profile, highlighting specific death and exposure statistics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
54
The slide uses a bar chart to compare reporting rates per million daily doses, with specific focus on drugs withdrawn from the market due to cardiac safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
55
The slide uses a calculation of daily doses sold based on revenue and price to derive a rate, then compares this against historical data from a Lancet study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
56
The slide uses a direct quote from scientific literature to establish a causal link between the drug's mechanism and its side effects.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
57
The slide uses a specific research paper abstract to validate the claim of inherent cardiotoxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
58
Includes a visual comparison of pharmacophore models and a specific reference to ABT-239.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
59
The slide highlights a fundamental design constraint in medicinal chemistry.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
60
The slide uses visual evidence to link a specific chemical moiety (piperidine) to a known safety liability (hERG blockade).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
61
The slide uses a combination of narrative text and a supporting data table to argue that certain structural features are predictive of drug safety risks.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
62
The slide highlights the specific chemical challenge of nitrogen basicity in piperidine rings and the potential for fluorine to modulate pKa for improved safety.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
63
The slide uses a screenshot of a blog post with red underlines to emphasize key quotes about hERG activity and piperidine.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
64
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
65
The slide uses a 'before-after' or 'evidence-based' contradiction structure to undermine the value of the licensed asset.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
66
The slide uses a 'quote-and-commentary' structure to expose potential corporate malfeasance or negligence.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
67
The slide uses historical publication data to cast doubt on the quality of the drug pitolisant by highlighting that the inventor prioritized other compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
68
The slide uses a 'fraud-exposure' narrative, highlighting a specific omission in a scientific paper to imply corporate malfeasance.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
69
The slide uses a question as a hook to frame the subsequent investigation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
70
The slide uses a 'villain' framing by highlighting the industry-wide failure of a specific drug class.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
71
The slide uses a combination of chemical structure diagrams, a tabular summary of clinical trial failures, and a pie chart showing the distribution of indications for failed trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
72
The slide highlights BF2.649 (pitolisant) with a red box to emphasize its drug-likeness profile compared to other failed candidates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
73
The slide uses a 'preempt_rebuttal' strategy by highlighting that even industry giants failed where the current subject company is operating.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
74
The slide uses a combination of narrative summary and a direct excerpt from a scientific review paper to validate the difficulty of the target.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
75
The slide uses a 'before-after' narrative structure to show that shifting chemical scaffolds did not solve the underlying safety issues in H3 receptor drug development.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
76
The slide uses excerpts from scientific literature to frame the technical hurdles in CNS drug development.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
77
The slide uses a 'villain critique' approach by leveraging a peer's own research to undermine the target's (Bioprojet/pitolisant) technology.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
78
The slide is currently empty of content other than the title, suggesting it is a placeholder or a transition slide for a section on competitor failures.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
79
The slide uses a forensic literature review approach to highlight historical concerns about the drug's safety profile (cardiotoxicity, bioavailability, etc.) that were allegedly ignored or suppressed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
80
The slide uses a primary text block to summarize the contradiction, followed by a direct excerpt from a 2008 paper as evidence.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
81
The slide uses a direct quote from a scientific paper to undermine the viability of the drug candidate mentioned in the lower text block.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
82
The slide uses a 'villain critique' style to undermine the target drug (pitolisant) by associating it with failed industry-wide efforts.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
83
The slide uses a Q&A format to present expert testimony as evidence of product failure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
84
The slide uses a Q&A transcript format to build a case against the efficacy of pitolisant based on historical failures at Abbott.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
85
The slide uses a Q&A format to build a case against the drug's efficacy based on metabolic pathways.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
86
The slide uses a Q&A format to frame the failure as a known, expected outcome rather than a surprise, highlighting the difficulty of the H3 class.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
87
The slide uses a Q&A transcript format to validate the thesis that the drug class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
88
Uses expert quotes to establish a 'villain' (the drug class/mechanism) and preemptively rebut its efficacy.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
89
The slide uses expert testimony to undermine the credibility of the company (Bioprojet) and the drug (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
90
The slide uses a Q&A transcript format to validate a negative thesis about the viability of H3 receptor programs.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
91
The slide uses a Q&A transcript format to validate the thesis that the H3 receptor class is fundamentally flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
92
The slide uses a Q&A transcript format to highlight a specific failure case study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
93
The slide uses a Q&A format to build a case against the safety of a drug program.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
94
The slide uses a Q&A transcript format to corroborate previous claims about drug instability and poor blood-brain barrier penetration.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
95
The slide uses expert testimony to establish a precedent of failure in the H3 receptor space, specifically contrasting J&J's robust trials with Bioprojet's pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
96
The slide uses a Q&A format to discredit the competitor's R&D rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
97
The slide uses highlighted text to emphasize key claims about compound quality and pharmacokinetic challenges.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
98
The slide uses direct quotes from a J&J scientist to undermine the credibility of Bioprojet's research capabilities.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
99
The slide uses a combination of summary bullet points and direct quotes from a consultation call to discredit the competitor's scientific rigor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
100
The slide uses highlighted text to emphasize key quotes from expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
101
The slide uses Q&A format to highlight potential industry knowledge of safety risks that were not publicly disclosed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
102
Uses Q&A format to frame expert opinion as a critique of Bioprojet's claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
103
The slide presents two distinct expert critiques regarding IP expiration and clinical trial quality, attributed to a senior scientist at Johnson & Johnson.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
104
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
105
The slide uses a 'quote-and-critique' structure to expose potential data manipulation in clinical reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit